Oncorus Appoints Scott Canute to its Board of Directors
Oncorus Appoints Scott Canute to its Board of Directors Oncorus Appoints Scott Canute to its Board of Directors CAMBRIDGE, Mass., Dec. 14, 2020 — Oncorus, Inc. (Nasdaq: ONCR), a clinical stage biopharmaceutical company developing next-generation viral immunotherapies to transform outcomes for cancer patients, today announced the appointment of Scott Canute, M.B.A. to its Board of Directors. Mr. Canute has nearly 40 years of broad experience in the biopharmaceutical industry, including leading global manufacturing and operations strategy and execution for Genzyme Corporation and Eli Lilly an...
Source: globalbankingandfinance.com